Skip to main content

Does Skyrizi cause hair loss?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on June 3, 2024.

Official answer

by Drugs.com

No, Skyrizi (risankizumab) did not cause hair loss during clinical trials. Skyrizi is an injectable medication used for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn’s disease.

Hair loss wasn’t reported as a side effect during clinical trials submitted to the FDA for approval. It is not included as a side effect in the Skyrizi product information. Additionally, hair loss wasn’t identified as a side effect due to Skyrizi in a long-term study of 17 clinical trials of patients taking the medication to treat plaque psoriasis.

If you notice hair thinning or hair loss (also called alopecia), talk to your doctor. There are many causes of hair loss, including stress, diet changes, and certain medications. Your doctor can help you determine what is causing your hair loss and provide recommendations for treating it.

References

Gordon, K. B., et. al. (2022). Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis. In: British Journal of Dermatology. Accessed on 06/03/2024 at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298814/

Skyrizi [package insert]. Revised March 2024. AbbVie Inc. Accessed 06/03/2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7148c8eb-b39e-e20a-6494-a6df82392858

Read next

Psoriasis typically appears as a red, dry, and flaky patch of skin, and may be covered with white scales called plaques. It can occur on any area of the body, including hands, feet, elbows, scalp or genitals. Psoriasis can feel itchy, sore, burning and the skin may feel tight, crack or bleed. Frequent itching can lead to thicker areas of plaques. Continue reading

Ilumya works by binding selectively to interleukin-23 (IL-23) which is a naturally occurring cytokine. IL-23 plays a key role in promoting inflammation and regulating other cytokines (such as IL-17) and inflammatory substances, such as TNF-α3-7. By blocking the effects of IL-23, Ilumya helps control the release of IL-17 and TNF-α, which reduces inflammation associated with psoriasis. It also decreases how many inflammatory cells are present within psoriatic lesions, helps prevent plaque formation, and resolves tissue damage. Continue reading

Prednisone first came onto the market over sixty years ago and is still going strong. But did you know that this common drug used for a variety of different conditions also has some pretty serious side effects as well? Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer